Please login to the form below

BOLDSCIENCE welcomes Steven Cohen to its leadership team to expand its strategic communication consulting services into regulatory approvals

Medical communications agency BOLDSCIENCE has hired industry veteran Steven Cohen to lead a new division that will help pharmaceutical and biotech clients navigate the most critical challenges they face throughout the product lifecycle, with a focus on product approvals.

Medical communications agency BOLDSCIENCE has hired Steven Cohen as Executive Vice President and Managing Director. He will lead a new division focused on product approvals that will offer a range of clinical and regulatory communications services. The division will bridge the gap between traditional medcomms services for investigational products and for commercial products so that industry innovator BOLDSCIENCE can seamlessly support clients throughout the product lifecycle. This is the latest from the forward-thinking agency, which offers scientifically creative medcomms services to clients looking for a trusted partner with cutting-edge capabilities.

To deliver success for their clients in this challenging arena, BOLDSCIENCE has tapped Steven Cohen, a leader with over 30 years of communication consultancy experience. Steven has prepared over 100 global teams for FDA Advisory Committee meetings, supported health authority interactions at other key milestones, and led submission messaging workshops. He plans for BOLDSCIENCE to offer these same services within the new division, as well as communication training seminars, and private coaching on presentation and Q&A skills.

Commenting on his new role, Steven says “My passion is helping clients achieve their goals through persuasive and compelling communications. There is no time more critical to do this than during a products regulatory filing and review.”

“I am thrilled to be working with the BOLDSCIENCE team to add another dimension to their existing strategic services for drugs, biologics, and devices. Our combined extensive communication experience, deep scientific understanding, and world-class project management will provide a differentiated service to clients across the product lifecycle,” says Steven.

Commenting on the new division, Mark Lydiatt, BOLDSCIENCE’s Chief Executive Officer, says “We have the opportunity to offer clients an unrivalled communication consultancy integrated into our existing medical communications offerings. We believe that under Steven’s leadership, we will raise the bar on consulting services, offer unique continuity and efficiency for our clients, and expand career-development opportunities for our staff.”

“We’re excited about the synergies our clients will experience with the integration of these new services. They will benefit from our therapeutic area expertise being brought into the approval process within an integrated solution that will facilitate not just approval but commercialization and market access,” says Alison Lovibond, Chief Scientific Officer.

BOLDSCIENCE plans to enlarge the consulting team in the US and EU as their work continues to grow with clients globally.

For further information, please visit www.boldsci.com, or contact us at hello@boldsci.com.

30th September 2021

Share

Tags

Company Details

BOLDSCIENCE

+1 4704084986

Contact Website

Address:
15 Bishopsgate
London
EC2N 3AR
United Kingdom